Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,001 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Subsequent Upper Urinary Tract Carcinoma Related to Worse Survival in Patients Treated with BCG.
Numakura K, Miyake M, Kobayashi M, Muto Y, Sekine Y, Nishimura N, Iida K, Shiga M, Morizane S, Yoneyama T, Matsumura Y, Abe T, Yamada T, Matsumoto K, Inokuchi J, Nishiyama N, Taoka R, Kobayashi T, Kojima T, Kitamura H, Nishiyama H, Fujimoto K, Habuchi T. Numakura K, et al. Among authors: sekine y. Cancers (Basel). 2023 Mar 28;15(7):2002. doi: 10.3390/cancers15072002. Cancers (Basel). 2023. PMID: 37046663 Free PMC article.
Severe Immune-Related Adverse Events in Patients Treated with Nivolumab for Metastatic Renal Cell Carcinoma Are Associated with PDCD1 Polymorphism.
Kobayashi M, Numakura K, Hatakeyama S, Muto Y, Sekine Y, Sasagawa H, Kashima S, Yamamoto R, Koizumi A, Nara T, Saito M, Narita S, Ohyama C, Habuchi T. Kobayashi M, et al. Among authors: sekine y. Genes (Basel). 2022 Jul 5;13(7):1204. doi: 10.3390/genes13071204. Genes (Basel). 2022. PMID: 35885987 Free PMC article.
Primary resistance to nivolumab plus ipilimumab therapy in patients with metastatic renal cell carcinoma.
Numakura K, Sekine Y, Hatakeyama S, Muto Y, Sobu R, Kobayashi M, Sasagawa H, Kashima S, Yamamto R, Nara T, Akashi H, Tabata R, Sato S, Saito M, Narita S, Ohyama C, Habuchi T. Numakura K, et al. Among authors: sekine y. Cancer Med. 2023 Aug;12(16):16837-16845. doi: 10.1002/cam4.6306. Epub 2023 Jul 5. Cancer Med. 2023. PMID: 37403728 Free PMC article.
Real clinical outcomes of nivolumab plus ipilimumab for renal cell carcinoma in patients over 75 years old.
Kobayashi M, Numakura K, Hatakeyama S, Ishida T, Koizumi A, Tadachi K, Igarashi R, Takayama K, Muto Y, Sekine Y, Sobu R, Sasagawa H, Akashi H, Kashima S, Yamamoto R, Nara T, Saito M, Narita S, Ohyama C, Habuchi T. Kobayashi M, et al. Among authors: sekine y. Int J Clin Oncol. 2023 Nov;28(11):1530-1537. doi: 10.1007/s10147-023-02394-y. Epub 2023 Aug 8. Int J Clin Oncol. 2023. PMID: 37552353
The Current Trend of Radiation Therapy for Patients with Localized Prostate Cancer.
Numakura K, Kobayashi M, Muto Y, Sato H, Sekine Y, Sobu R, Aoyama Y, Takahashi Y, Okada S, Sasagawa H, Narita S, Kumagai S, Wada Y, Mori N, Habuchi T. Numakura K, et al. Among authors: sekine y. Curr Oncol. 2023 Sep 1;30(9):8092-8110. doi: 10.3390/curroncol30090587. Curr Oncol. 2023. PMID: 37754502 Free PMC article. Review.
The lymphocyte-to-monocyte ratio as a significant inflammatory marker associated with survival of patients with metastatic renal cell carcinoma treated using nivolumab plus ipilimumab therapy.
Numakura K, Sekine Y, Osawa T, Naito S, Tokairin O, Muto Y, Sobu R, Kobayashi M, Sasagawa H, Yamamoto R, Nara T, Saito M, Narita S, Akashi H, Tsuchiya N, Shinohara N, Habuchi T. Numakura K, et al. Among authors: sekine y. Int J Clin Oncol. 2024 Jul;29(7):1019-1026. doi: 10.1007/s10147-024-02538-8. Epub 2024 May 26. Int J Clin Oncol. 2024. PMID: 38797782
1,001 results